Seres Therapeutics Inc (NASDAQ:MCRB) has received a consensus recommendation of “Buy” from the twelve ratings firms that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $19.14.
A number of analysts have recently weighed in on MCRB shares. Zacks Investment Research upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 14th. BidaskClub cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, February 7th.
Hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC bought a new position in Seres Therapeutics during the third quarter worth $2,165,000. Northern Trust Corp increased its position in Seres Therapeutics by 16.2% during the second quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock worth $2,664,000 after acquiring an additional 32,875 shares during the period. JPMorgan Chase & Co. increased its position in Seres Therapeutics by 39.9% during the third quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock worth $6,160,000 after acquiring an additional 106,479 shares during the period. State Street Corp increased its position in Seres Therapeutics by 12.0% during the second quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock worth $3,637,000 after acquiring an additional 34,393 shares during the period. Finally, Lakeview Capital Partners LLC bought a new position in Seres Therapeutics during the fourth quarter worth $346,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.
Shares of Seres Therapeutics (NASDAQ:MCRB) traded up $0.24 during trading on Friday, hitting $8.87. 89,953 shares of the stock were exchanged, compared to its average volume of 147,224. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.53 and a quick ratio of 6.53. Seres Therapeutics has a twelve month low of $7.90 and a twelve month high of $17.42. The firm has a market capitalization of $351.80, a PE ratio of -4.18 and a beta of 0.24.
ILLEGAL ACTIVITY NOTICE: “Brokerages Set Seres Therapeutics Inc (MCRB) Price Target at $19.14” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/15/brokerages-set-seres-therapeutics-inc-mcrb-price-target-at-19-14.html.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.